Compounds > 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one
Page last updated: 2024-08-26

7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one and Precursor Cell Lymphoblastic Leukemia-Lymphoma

7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goso, C; Manzini, S; Potier, E; Szallasi, A1

Other Studies

1 other study(ies) available for 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one and Precursor Cell Lymphoblastic Leukemia-Lymphoma

ArticleYear
Comparison of tachykinin NK1 receptors in human IM9 and U373 MG cells, using antagonist (FK888, (+/-)-CP-96,345, and RP 67580) binding.
    European journal of pharmacology, 1994, Mar-21, Volume: 254, Issue:3

    Topics: Astrocytoma; Biphenyl Compounds; Dipeptides; Humans; Indoles; Isoindoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Neurokinin-1; Substance P; Tumor Cells, Cultured

1994